Lastly, the company also said it would offer a 1-time insulin supply option for no cost for when supply has run out and the patient might be in danger of skipping or rationing their doses. The supply would include 3 vials or 2 packs of pens for those with a prescription. Last year, stories of insulin rationing by patients were heard at various hearings before Congressional committees discussing the issue of high drug costs in America.
A report last June said insulin rationing is a problem globally , but worse in the United States. The FDA is hoping that the transition to regulating insulin as a biologic in March will help increase competition. Morgan Healthcare Conference, with presentations likely geared towards their future pipeline.
On Monday, the FDA expanded the company's fast-acting mealtime insulin aspart, marketed as Fiasp, for use in children as young as two. The product was first approved by the FDA in for adults for use by intravenous injection in a medical setting or by subcutaneous multiple daily injections. By study end:. Adverse reactions observed with NovoLog include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash and pruritis. Novo Nordisk is a healthcare company with an year history of innovation and achievement in diabetes care.
The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers.
With headquarters in Denmark, Novo Nordisk employs more than 26, employees in 80 countries, and markets its products in countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
0コメント